Comprehensive Biomarker and Molecular Testing Decision Tree: Optimizing Tissue Acquisition, Panel Selection, and Targeted Therapy Matching

A practical, tumor-board-ready workflow from biopsy to actionable result — how to conserve tissue, choose between reflex single-gene testing, comprehensive genomic profiling, and liquid biopsy, and match each lineage's biomarkers to the right targeted therapy, immunotherapy, or antibody-drug conjugate

Key Points

• Precision oncology has shifted first-line decision-making from empiric, histology-based chemotherapy to biomarker-driven therapy selection — but the quality of that decision is capped by the quality and quantity of the tissue tested.
• Tumor cellularity matters as much as tissue volume: most next-generation sequencing (NGS) assays require a target of ≥20% neoplastic cells, and a low-cellularity sample can produce false-negative results that misdirect therapy.
• The core upfront decision is reflex single-gene testing (fast, cheap, narrow — ideal for emergency targets like EGFR/ALK in lung or BRAF in melanoma) versus comprehensive genomic profiling (CGP/NGS, DNA + RNA), which preserves tissue by testing everything at once.
• Liquid biopsy (plasma ctDNA) is the primary rescue path when tissue is scarce, exhausted, or the patient cannot safely be re-biopsied; a positive result is actionable, but a negative result is inconclusive and must be confirmed on tissue.
• Every advanced solid tumor should have both an IHC/protein-marker workup and a DNA/RNA NGS workup — the two modalities answer different questions (protein expression and mismatch-repair status vs. sequence and fusion alterations).
• In NSCLC the mandatory panel is PD-L1 (TPS/CPS) plus EGFR, ALK, ROS1, BRAF, MET exon 14, RET, KRAS G12C, and NTRK; in colorectal cancer it is MMR/MSI plus KRAS, NRAS, BRAF V600E, and HER2; in metastatic breast cancer it is ER/PR/HER2 plus PIK3CA, AKT1, PTEN, and BRCA1/2.
• The AMP/ASCO/CAP tier system (Tiers I–IV) standardizes how variants are reported by clinical actionability, keeping the molecular tumor board focused on Tier I/II findings that change management today.
• Testing is not a one-time event: acquired resistance should be interrogated at progression with repeat tissue or liquid biopsy to detect resistance mechanisms (e.g., EGFR T790M/C797S, MET amplification) that open the next line of therapy.

Introduction & Clinical Rationale

For most of the history of medical oncology, systemic therapy was chosen empirically: a tumor's organ of origin and its appearance under the microscope dictated a standard chemotherapy regimen applied to everyone with that diagnosis. Precision oncology has replaced that paradigm. Today, the molecular fingerprint of an individual tumor — its driver mutations, gene fusions, copy-number changes, protein expression, and genomic instability — frequently determines first-line therapy, and matching the right patient to the right targeted agent can be the single largest determinant of outcome. That…

Step 1 — Tissue Optimization & Pathology Triage

Everything downstream depends on the specimen. Before any molecular assay is ordered, the pathologist must assess two things: how much tissue is present, and what fraction of it is actually tumor. Tumor cellularity is the more commonly overlooked variable. Most NGS assays are validated to a limit of detection that assumes a target of at least 20% neoplastic cells; below that threshold, a true driver mutation present in only a minority of cells can fall beneath the assay's sensitivity and be reported — falsely — as absent. Macrodissection or micro-dissection to enrich the tumor fraction, and…

Step 2 — Disease-Specific Biomarker Matrix: NSCLC

Non-small cell lung cancer is the archetype of biomarker-driven care and carries the largest mandatory testing panel of any common solid tumor. Guidelines require that every patient with advanced non-squamous NSCLC (and increasingly squamous disease) have comprehensive profiling before first-line therapy, because the number of actionable drivers is large and the therapeutic consequences are decisive. On the protein/IHC side, PD-L1 expression — reported as a Tumor Proportion Score (TPS) — determines eligibility for immunotherapy, with a TPS ≥50% supporting single-agent checkpoint blockade. On…

Step 2 — Disease-Specific Biomarker Matrix: Gastrointestinal (CRC & Gastric)

In colorectal cancer, the biomarker workup governs two independent therapeutic decisions: whether anti-EGFR antibody therapy is viable, and whether immunotherapy is an option. The IHC/protein workup centers on mismatch-repair (MMR) protein status: loss of one or more of MLH1, MSH2, MSH6, or PMS2 by immunohistochemistry defines mismatch-repair deficiency (dMMR), which corresponds to microsatellite instability-high (MSI-H) status on molecular testing. MSI-H/dMMR tumors are exquisitely sensitive to checkpoint blockade — this is the strongest, tumor-agnostic predictor of immunotherapy benefit…

Step 2 — Disease-Specific Biomarker Matrix: Metastatic Breast Cancer

Breast cancer profiling begins with the three classic receptors and then extends into a growing panel of actionable somatic and germline alterations. The foundational IHC/protein workup is estrogen receptor (ER), progesterone receptor (PR), and HER2, with HER2 equivocal cases reflexed to FISH. These define the three canonical subtypes — hormone-receptor-positive/HER2-negative, HER2-positive, and triple-negative — that dictate the entire treatment backbone, from endocrine therapy plus a CDK4/6 inhibitor, to HER2-directed antibodies and antibody-drug conjugates (ADCs), to chemotherapy with or…

Step 3 — Actionability & the AMP/ASCO/CAP Tier Framework

A comprehensive NGS report can list dozens of variants, most of which are biologically irrelevant passengers. The AMP/ASCO/CAP consensus guideline provides the standardized four-tier system that clinical laboratories use to rank somatic variants by clinical actionability, keeping the molecular tumor board focused on what actually changes management. Tier I — variants of strong clinical significance — includes alterations with an FDA-approved therapy or those included in professional guidelines for that tumor type (Level A), and those that are the standard of care in a different tumor type or…

Liquid Biopsy, Resistance Monitoring & Re-Testing

Molecular profiling is not a single event at diagnosis — it is a longitudinal process that should be revisited when the disease changes. Liquid biopsy, which detects circulating tumor DNA (ctDNA) shed into the plasma, has two principal roles. First, it is the rescue pathway when tissue is insufficient or a re-biopsy is unsafe: a plasma NGS panel can identify actionable drivers without any tissue at all. The crucial interpretive rule is asymmetric — a positive ctDNA result is actionable and can be acted upon, but a negative result is inconclusive, because a tumor that sheds little DNA can be…